Glenmark Pharma: Plans To Achieve 115 Days Of Net Working Capital By March '26, Currently At About 110 Days, And Aims To Have Zero Gross Debt By March '26. The Company Expects Annual Capital Expenditure Of INR 700-800 Crores, With INR 800 Crores Slated For Next Year Mainly For Plant Expansion And In-Licensing.

 03 Feb 2026 09:01 AM

Glenmark Pharma: Plans To Achieve 115 Days Of Net Working Capital By March '26, Currently At About 110 Days, And Aims To Have Zero Gross Debt By March '26. The Company Expects Annual Capital Expenditure Of INR 700-800 Crores, With INR 800 Crores Slated For Next Year Mainly For Plant Expansion And In-Licensing.

Glenmark: Expects Strong End To FY26 And Good Start To "Glenmark 3.0" Growth Journey In 2027, Aiming To Meet Overall Goals. Company Targets Sustainable EBITDA Margin Of 23% For This Year and Coming Quarters, Expecting Significant Margin Increase From FY28 Due To New Innovations

 03 Feb 2026 09:01 AM

Glenmark: Expects Strong End To FY26 And Good Start To "Glenmark 3.0" Growth Journey In 2027, Aiming To Meet Overall Goals. Company Targets Sustainable EBITDA Margin Of 23% For This Year and Coming Quarters, Expecting Significant Margin Increase From FY28 Due To New Innovations

Glenmark Pharma: Plans Expansion With New Approvals. The US division anticipates strong growth in Q4 FY26 from respiratory product launches, including a probable FloVent 44 approval, while the Monroe site will begin commercial production in the same quarter, aiming for three annual filings. New product approvals are expected in Q4, which may boost gross margins.

 03 Feb 2026 09:02 AM

Glenmark Pharma: Plans Expansion With New Approvals. The US division anticipates strong growth in Q4 FY26 from respiratory product launches, including a probable FloVent 44 approval, while the Monroe site will begin commercial production in the same quarter, aiming for three annual filings. New product approvals are expected in Q4, which may boost gross margins.

Glenmark Pharma: Seeks Regulatory Approvals with Two ANDAs Submitted for North America in Q3 and Three More Planned for Next Quarter, Including Generic Flovent 110 and Two Generic Nasal Sprays.

 03 Feb 2026 09:02 AM

Glenmark Pharma: Seeks Regulatory Approvals with Two ANDAs Submitted for North America in Q3 and Three More Planned for Next Quarter, Including Generic Flovent 110 and Two Generic Nasal Sprays.

GLENMARK PHARMA: Q3 CONS NET PROFIT 4B RUPEES VS 3.5B (YOY); EST 6.3B || Q3 REVENUE 39B RUPEES VS 33B (YOY)

 30 Jan 2026 08:13 PM

GLENMARK PHARMA: Q3 CONS NET PROFIT 4B RUPEES VS 3.5B (YOY); EST 6.3B || Q3 REVENUE 39B RUPEES VS 33B (YOY)

GLENMARK PHARMA: Q3 EBITDA 9B RUPEES VS 6B (YOY) || Q3 EBITDA MARGIN 23.19% VS 18.18% (YOY)

 30 Jan 2026 08:14 PM

GLENMARK PHARMA: Q3 EBITDA 9B RUPEES VS 6B (YOY) || Q3 EBITDA MARGIN 23.19% VS 18.18% (YOY)

GLENMARK PHARMA: CO HAS EXCEPTIONAL ITEM OF 1.84B RUPEES || Q3 PBT 7.2B RUPEES VS 4.6B (YOY)

 30 Jan 2026 08:15 PM

GLENMARK PHARMA: CO HAS EXCEPTIONAL ITEM OF 1.84B RUPEES || Q3 PBT 7.2B RUPEES VS 4.6B (YOY)

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Introduces New Epinephrine Injection USP, 30 MG/30 ML (1 MG/ML) Multiple-Dose Vial

 23 Dec 2025 09:04 AM

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Introduces New Epinephrine Injection USP, 30 MG/30 ML (1 MG/ML) Multiple-Dose Vial

Glenmark Pharma: Co Signs Exclusive Deal With Hansoh Pharma For Aumolertinib Rights, Totaling Over $1 Billion Payment

 16 Dec 2025 03:47 PM

Glenmark Pharma: Co Signs Exclusive Deal With Hansoh Pharma For Aumolertinib Rights, Totaling Over $1 Billion Payment

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Set To Release Leucovorin Calcium For Injection USP, Starting December 2025.

 11 Dec 2025 08:45 AM

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Set To Release Leucovorin Calcium For Injection USP, Starting December 2025.

Glenmark Pharmaceuticals: U.S. FDA Finishes Inspection At Co's Chhatrapati Sambhajinagar Facility With No Issues Found.

 01 Dec 2025 09:04 AM

Glenmark Pharmaceuticals: U.S. FDA Finishes Inspection At Co's Chhatrapati Sambhajinagar Facility With No Issues Found.

Glenmark Pharmaceuticals: Gets VAI Status From U.S. FDA For Monroe Facility, Resuming Commercial Manufacturing

 27 Nov 2025 10:16 AM

Glenmark Pharmaceuticals: Gets VAI Status From U.S. FDA For Monroe Facility, Resuming Commercial Manufacturing

Glenmark Pharmaceuticals: Introduces First Nebulized Triple Treatment For COPD That Combines Glycopyrrolate, Formoterol, And Budesonide To Enhance Lung Function And Control Symptoms

 25 Nov 2025 09:04 AM

Glenmark Pharmaceuticals: Introduces First Nebulized Triple Treatment For COPD That Combines Glycopyrrolate, Formoterol, And Budesonide To Enhance Lung Function And Control Symptoms

Glenmark Pharma: HSBC on Glenmark Pharma Buy, target price cut to Rs 2110

 19 Nov 2025 09:04 AM

Glenmark Pharma: HSBC on Glenmark Pharma Buy, target price cut to Rs 2110

Glenmark Pharmaceuticals: Gets Approval To Market Winlevi® Cream In 15 European Countries For Treating Acne In Adults And Teens.

 18 Nov 2025 02:41 PM

Glenmark Pharmaceuticals: Gets Approval To Market Winlevi® Cream In 15 European Countries For Treating Acne In Adults And Teens.

Glenmark Pharma: Aims For 12-15% Revenue Growth With Initial EBITDA Margins Of 23%, Planning To Reach 25% Plus Later. They Target Return Ratios Of 25-30% ROCE And 20-25% ROE. The IGI Subsidiary Plans Annual Spending Of $70-75 Million

 18 Nov 2025 09:02 AM

Glenmark Pharma: Aims For 12-15% Revenue Growth With Initial EBITDA Margins Of 23%, Planning To Reach 25% Plus Later. They Target Return Ratios Of 25-30% ROCE And 20-25% ROE. The IGI Subsidiary Plans Annual Spending Of $70-75 Million

Glenmark Pharma: Sets Quarterly Revenue Goals Of ₹1,150-1,200 Crores From Q3 FY26 And Over ₹4,800 Crores For FY27, Targeting Total Revenue Of ₹17,000-18,000 Crores For FY27.

 18 Nov 2025 08:54 AM

Glenmark Pharma: Sets Quarterly Revenue Goals Of ₹1,150-1,200 Crores From Q3 FY26 And Over ₹4,800 Crores For FY27, Targeting Total Revenue Of ₹17,000-18,000 Crores For FY27.

Glenmark Pharma: Co Management Says That It Aims To Grow Revenues 15% Yearly Going Forward || Co Says That They Aim On Their EBITDA Margin Moving Up To 25% Going Forward And The Co Is Aiming To Be Gross Debt Free In The Coming Time - Concall Updates

 17 Nov 2025 09:41 AM

Glenmark Pharma: Co Management Says That It Aims To Grow Revenues 15% Yearly Going Forward || Co Says That They Aim On Their EBITDA Margin Moving Up To 25% Going Forward And The Co Is Aiming To Be Gross Debt Free In The Coming Time - Concall Updates

Glenmark Pharma: Co Expects Sales in India to Recover from Q3, Aiming for ₹1150-1200 Crore From Q3 This Year and ₹4800 Crore for the Next Year -Concall Updates

 17 Nov 2025 09:16 AM

Glenmark Pharma: Co Expects Sales in India to Recover from Q3, Aiming for ₹1150-1200 Crore From Q3 This Year and ₹4800 Crore for the Next Year -Concall Updates

Glenmark Pharma: Co Management Says That In FY26 The Co Will Surely Be A Gross Debt Zero Co - Concall Updates

 17 Nov 2025 09:24 AM

Glenmark Pharma: Co Management Says That In FY26 The Co Will Surely Be A Gross Debt Zero Co - Concall Updates